Diagnostics for the Real World Ltd (DRW) has announced that it has achieved UK technical validation for its SARS-CoV-2/FluA/FluB and SARS-CoV-2/RSV tests. The tests will enable clinicians to detect and differentiate between coronavirus SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV).
Dr Ravi Gupta, professor of clinical microbiology at the Cambridge Institute for Therapeutic Immunology and Infectious Disease, who led the initial validation of the tests, said: “With COVID remaining an ongoing challenge, prompt differential diagnosis of respiratory viruses continues to be extremely important for effectively managing patient care pathways and workflows in hospitals – from reducing the requirement for COVID ‘holding areas’ on admission and enabling faster triage, to freeing up much-needed beds on wards and allowing safe discharge to out-of-hospital settings, including to care homes."
"DRW’s new multiplex tests will be welcomed by clinicians as a key tool to help speed access to urgent care, crucially emergency surgery, and transplantation, where delays and co-infections can have very significant adverse impacts.”
DRW is responsible for developing the SAMBA platform for rapid point-of-care detection of infectious diseases. Using its SAMBA II system, which can be operated with minimal training, accurate results can be gathered instantly.
Dr Helen Lee, chairman and CEO of DRW, added: “Our team is focused on developing and delivering practical near-patient solutions that provide the highest value at the greatest point of need. From our ongoing COVID-19 testing work in the NHS and in discussions with hospital staff, the requirement for fast, accurate multiplex respiratory virus tests for use in clinical practice was clear and urgent."
"These new tests deliver on the first stage of our plan to expand our menu of tests available on the SAMBA II platform – supporting rapid, efficient, and accurate diagnosis of multiple infectious diseases, aiding clinical decision-making, and enabling improved, timely access to healthcare for all.”
DRW’s fully automated ‘sample in, result out’ diagnostic machine, is currently deployed in over 100 UK hospital sites. The two new multiplex tests will also be available to NHS hospitals and healthcare settings.